Saxenda vs Semaglutide: Which GLP-1 Is Right for You?

Saxenda was a breakthrough when it launched in 2015. The first GLP-1 medication specifically FDA-approved for weight loss (at 3mg daily), it represented a paradigm shift in obesity medicine. Daily injections. Meaningful appetite suppression. Clinically significant weight loss in trials.

Then semaglutide arrived. And the comparison has been one-sided ever since.

Understanding why Saxenda lost its dominant position — and what that means if you're choosing between them — requires a look at the actual clinical data, the mechanism differences, and the practical realities of daily vs. weekly injections.

What Is Saxenda?

Saxenda is liraglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. It's the same active ingredient as Victoza, which is FDA-approved for type 2 diabetes at 1.8mg. Saxenda targets 3mg daily for weight management.

Liraglutide has a half-life of approximately 13 hours, which is why it requires daily injection. It binds to and activates GLP-1 receptors in the brain and gut, reducing appetite and slowing gastric emptying.

What Is Semaglutide?

Semaglutide (Ozempic for diabetes, Wegovy for weight management) is also a GLP-1 receptor agonist, also from Novo Nordisk. Its half-life is approximately 7 days — which is why it's dosed once weekly. Semaglutide was engineered with structural modifications (specifically, a fatty acid chain attached to a slightly modified GLP-1 backbone) that dramatically extend its duration of action and increase its binding affinity.

The Clinical Trial Data

Liraglutide (SCALE trial): - 56-week trial of liraglutide 3mg vs. placebo in adults with overweight/obesity - Average weight loss: ~8% of body weight (vs. 2.6% placebo) - 63% of patients lost ≥5% body weight - 33% lost ≥10%

Semaglutide (STEP 1 trial): - 68-week trial of semaglutide 2.4mg vs. placebo - Average weight loss: ~15% of body weight (vs. 2.4% placebo) - 86% of patients lost ≥5% body weight - 70% lost ≥10% - 32% lost ≥20%

The difference isn't marginal. Semaglutide produces roughly twice the weight loss of liraglutide at similar trial durations. This gap held up in real-world data and is the primary reason most obesity medicine specialists moved to semaglutide as the first-line GLP-1 for weight management.

Why Is Semaglutide More Effective?

Several factors explain the superior efficacy:

1. Longer half-life = more sustained receptor activation Liraglutide provides ~13 hours of coverage. Between daily doses, GLP-1 receptor activity drops. Semaglutide's 7-day half-life provides near-constant receptor occupation — meaning appetite suppression is present 24/7, including overnight when many people snack.

2. Higher receptor binding affinity Semaglutide's structural modifications increase its affinity for GLP-1 receptors. More potent activation of the same receptors produces stronger downstream effects.

3. Higher achievable dose The maximum liraglutide dose for weight management is 3mg daily. Semaglutide can be titrated to 2.4mg weekly (equivalent to much higher daily exposure). The dose-response curve of GLP-1 receptor agonists favors semaglutide's range.

4. Central vs. peripheral effects Semaglutide appears to have greater central nervous system penetration, more strongly modulating the hypothalamic circuits that control appetite and food reward behavior.

Tolerability: Daily vs. Weekly Injections

Injection frequency matters practically. Daily liraglutide injections mean 365 injections per year. Weekly semaglutide means 52.

For GI side effects (nausea, vomiting, diarrhea), the profiles are broadly similar — both are GLP-1 agonists with the same mechanism of action on the gut. Semaglutide may have slightly higher peak GI effects given its longer half-life, but real-world adherence tends to be significantly better with once-weekly dosing.

Multiple studies show patients are more likely to remain on weekly injections than daily injections. Adherence drives outcomes. Better adherence → better weight loss → higher patient satisfaction.

Cost: Where Saxenda Has (Had) an Advantage

Historically, brand-name Saxenda was slightly less expensive than Wegovy. Today, both run $900-1,200+/month without insurance, with similar coupon programs.

The real cost shift came with compounded semaglutide. Compounding pharmacies can produce high-quality semaglutide at a fraction of the brand-name cost — Marrow offers it starting at $249/month. Compounded liraglutide exists but is much less common, and the availability gap continues to widen.

If cost is your primary concern, compounded semaglutide is almost universally the better value than any form of liraglutide today.

When Saxenda Might Still Make Sense

Pregnancy history and planning. Semaglutide has a longer washout period (5+ weeks) compared to liraglutide (~3 weeks). For women planning pregnancy in the near term, liraglutide offers a faster return to medication-free status.

Existing prescription continuity. Patients who've been stable and successful on liraglutide for years may not need to switch. The data shows semaglutide is more effective on average — but individual variation exists, and if you're losing weight consistently on Saxenda, the intervention isn't broken.

Specific contraindications. A small minority of patients have reactions or contraindications specific to semaglutide's structure (excipients, formulation). Liraglutide provides an alternative GLP-1 option.

The Bottom Line

If you're choosing a GLP-1 for weight loss today, the data strongly favors semaglutide: - Approximately 2x the weight loss - Once-weekly vs. daily injection - Compounded versions available at significantly lower cost

Saxenda was a landmark drug that opened the GLP-1 era in obesity medicine. But the field moved fast. Semaglutide replaced it as the standard of care within a few years of launch, and tirzepatide (dual GLP-1/GIP) has pushed efficacy even further.

If you're currently on Saxenda and have plateaued, a conversation about switching to semaglutide or tirzepatide is entirely appropriate. Most patients who switch see renewed weight loss relatively quickly.